

ARCA biopharma, Inc.
Form 3
November 02, 2012

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *		2. Date of Event Requiring Statement	3. Issuer Name and Ticker or Trading Symbol	
Â Atlas Venture Fund VII L P		(Month/Day/Year)	ARCA biopharma, Inc. [ABIO]	
(Last)	(First)	(Middle)	4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)
25 FIRST STREET, SUITE 303			(Check all applicable)	
(Street)			<input type="checkbox"/> Director	<input checked="" type="checkbox"/> 10% Owner
CAMBRIDGE,Â MAÂ 02141			<input type="checkbox"/> Officer	<input type="checkbox"/> Other
(City)	(State)	(Zip)	(give title below)	(specify below)
			6. Individual or Joint/Group Filing(Check Applicable Line)	
			<input type="checkbox"/> Form filed by One Reporting Person	
			<input checked="" type="checkbox"/> Form filed by More than One Reporting Person	

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	1,579,542 ⁽¹⁾	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of	

Edgar Filing: ARCA biopharma, Inc. - Form 3

				Shares		(I) (Instr. 5)	
Warrant to Purchase Common Stock	Â (2)	10/10/2013	Common Stock	75,449 (1)	\$ 9.7406	D	Â
Warrant to Purchase Common Stock	Â (2)	10/25/2017	Common Stock	238,034 (1)	\$ 0.3001	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Atlas Venture Fund VII L P 25 FIRST STREET, SUITE 303 CAMBRIDGE, MA 02141	Â	Â X	Â	Â
Atlas Venture Associates VII, L.P. 25 FIRST STREET, SUITE 303 CAMBRIDGE, MA 02141	Â	Â X	Â	Â

Signatures

Atlas Venture Fund VII, L.P. By: Atlas Venture Associates VII, L.P., its general partner By:
Atlas Venture Associates VII, Inc., its general partner /s/ Kristen Laguerre Name: Kristen
Laguerre Title: Vice President 11/02/2012

__Signature of Reporting Person Date

Atlas Venture Associates VII, L.P. By: Atlas Venture Associates VII, Inc., /s/ Kristen Laguerre
Name: Kristen Laguerre Title: Vice President 11/02/2012

__Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Atlas Venture Fund VII, L.P. ("AV VII") is the record holder of these securities. Atlas Venture Associates VII, L.P. ("AVA VII LP") is
(1) the sole general partner of AV VII. Each of AV VII and AVA VII LP disclaims beneficial ownership of the reported securities except to
the extent of their pecuniary interest therein.

(2) This warrant is immediately exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays
a currently valid OMB number.